Humana (NYSE:HUM) Receives “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Humana (NYSE:HUM) in a research note issued to investors on Friday, Benzinga reports. Cantor Fitzgerald currently has a $395.00 price target on the insurance provider’s stock.

Several other research firms also recently commented on HUM. Morgan Stanley initiated coverage on Humana in a report on Monday, June 24th. They issued an equal weight rating and a $374.00 target price on the stock. Deutsche Bank Aktiengesellschaft upped their price target on shares of Humana from $341.00 to $349.00 and gave the stock a hold rating in a research note on Friday, August 2nd. Oppenheimer lifted their target price on shares of Humana from $370.00 to $400.00 and gave the stock an outperform rating in a report on Thursday, August 1st. Truist Financial increased their price target on shares of Humana from $355.00 to $400.00 and gave the company a hold rating in a report on Monday, July 15th. Finally, JPMorgan Chase & Co. raised their price target on shares of Humana from $332.00 to $396.00 and gave the company a neutral rating in a research report on Wednesday, August 21st. Thirteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Humana currently has an average rating of Hold and a consensus price target of $398.70.

Humana Price Performance

HUM opened at $310.41 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The company has a market cap of $37.40 billion, a price-to-earnings ratio of 19.33, a price-to-earnings-growth ratio of 2.56 and a beta of 0.50. The stock has a fifty day simple moving average of $357.71 and a two-hundred day simple moving average of $345.60. Humana has a 12-month low of $298.61 and a 12-month high of $530.54.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. Humana’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business earned $8.94 EPS. Research analysts predict that Humana will post 16 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.14%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio is presently 22.04%.

Institutional Investors Weigh In On Humana

Hedge funds and other institutional investors have recently modified their holdings of the stock. CarsonAllaria Wealth Management Ltd. increased its holdings in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares in the last quarter. Hantz Financial Services Inc. bought a new position in shares of Humana in the second quarter worth approximately $35,000. Family Firm Inc. purchased a new stake in shares of Humana in the second quarter worth $37,000. Carolinas Wealth Consulting LLC raised its position in shares of Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after purchasing an additional 74 shares during the period. Finally, Hollencrest Capital Management purchased a new position in shares of Humana during the 2nd quarter valued at $40,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.